MS patients presented significantly higher antibody concentrations to MOG (p < 0.01), HERV‐W (p = 0.0142) and the HERV‐K peptides 4 (p < 0.01), 5 (p < 0.01), and 6 (p < 0.01) when compared to IIH patients (Figure 1). This evidence concerns the gene MOG and myeloid sarcoma.